2026 ICD-10-CM Diagnosis Code E32.0Persistent hyperplasia of thymus

ICD-10-CM Codes›E00–E89›E20-E35›E32

ICD-10-CM E32.0
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

E32.0 is a billable ICD-10-CM diagnosis code for persistent hyperplasia of thymus. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 814 through 816. Coders also document this condition as hypertrophy of thymus. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Other specified and unspecified endocrine disorders.

E32.0 no longer risk-adjusts for Medicare Advantage: it mapped to HCC 23 under the retired CMS-HCC V24 model through payment year 2025 but maps to no category in the live V28 model. It still risk-adjusts in the PACE (CMS-HCC V22) category 23, ESRD (V21) category 23, ESRD (V24) category 23, and RxHCC Part D (V08) category 43 for payment year 2026.

Code Identity

ICD-10-CM Code
E32.0
Billable Status
Yes — Valid for Submission
Code Describes
Persistent hyperplasia of thymus
Short Description
Persistent hyperplasia of thymus
Same as the full description in the CMS dataset.
Parent Code
Diseases of thymus

Code Classification

ChapterE00–E89Endocrine, nutritional and metabolic diseases
SectionE20-E35Disorders of other endocrine glands
CategoryE32Diseases of thymus
This CodeE32.0Persistent hyperplasia of thymus

Medicare Risk Adjustment (HCC)Billing

E32.0 no longer risk-adjusts for Medicare Advantage: it maps to no payment category in the live CMS-HCC V28 model, although it still risk-adjusts in the other CMS models shown below.

CMS-HCC V28 (Medicare Advantage Payment Model)
Not mapped
Dropped in V28 see all codes that no longer risk-adjust
Prior Model (CMS-HCC V24)
HCC 23
V24 retired last contributed to a Medicare Advantage risk score in payment year 2025
Other CMS Models
PACE (CMS-HCC V22): HCC 23 · ESRD (V21): HCC 23 · ESRD (V24): HCC 23
ESRD V21 weights: 0.013 dialysis, 0.234–0.359 functioning graft · ESRD V24 weights: 0.036 dialysis, 0.217–0.390 functioning graft
Part D (RxHCC)
RxHCC 43 — Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders
also risk-adjusts in the Part D prescription drug model (V08)

Source: CMS Payment Year 2026 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Hypertrophy of thymus
  • Persistent hyperplasia of thymus

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • Hypertrophy of thymus

Index to Diseases and InjuriesGuidance

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR END015
Other specified and unspecified endocrine disorders
Default principal diagnosis: inpatient Yes · outpatient Yes

Convert E32.0 to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
254.0 Persist hyperplas thymus
Exact Match The mapping is direct, with no qualifiers.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About E32.0Overview

What is the ICD-10 code for persistent hyperplasia of thymus?

The ICD-10-CM code for persistent hyperplasia of thymus is E32.0 (sometimes written as E320). It is billable on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Is E32.0 (Diseases of thymus) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report persistent hyperplasia of thymus on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What MS-DRG does E32.0 group to?

When persistent hyperplasia of thymus is the principal diagnosis on an inpatient stay, it groups to MS-DRG 814, 815, 816, with relative weights from 0.6320 to 2.1267 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of E32.0?

Under the General Equivalence Mappings, persistent hyperplasia of thymus converts to ICD-9-CM 254.0 (persist hyperplas thymus). The mapping is a direct match.

Does E32.0 risk-adjust for Medicare Advantage payment?

Not for Medicare Advantage. E32.0 mapped to HCC 23 in the retired CMS-HCC V24 model, which last determined payment in 2025, but it maps to no category in the live V28 model; see all codes that no longer risk-adjust. It still risk-adjusts in the PACE (CMS-HCC V22) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V21) category 23 (Other Significant Endocrine and Metabolic Disorders), ESRD (V24) category 23 (Other Significant Endocrine and Metabolic Disorders), and RxHCC Part D (V08) category 43 (Pituitary, Adrenal Gland, and Other Endocrine and Metabolic Disorders).